Theravance : Media

Thursday, July 22, 2010
Theravance Reports Second Quarter 2010 Financial Results
Thursday, July 8, 2010
Theravance to Report Second Quarter 2010 Financial Results on July 22, 2010
Wednesday, June 2, 2010
Theravance to Present at Investor Conferences in June 2010
Thursday, April 22, 2010
Theravance to Present at Investor Conferences in May 2010
Wednesday, April 21, 2010
Theravance Reports First Quarter 2010 Financial Results
Tuesday, April 20, 2010
Theravance to Webcast 2010 Annual Meeting of Stockholders on April 27, 2010
Wednesday, April 14, 2010
Theravance Announces Initiation of Proof of Concept Phase 2 Clinical Study with its PUMA Compound, TD-1211, for the Treatment of Opioid-Induced Constipation
Wednesday, April 7, 2010
Theravance to Report First Quarter 2010 Financial Results on April 21, 2010
Wednesday, March 24, 2010
Theravance Announces Closing of Public Offering of Common Stock
Friday, March 19, 2010
Theravance Announces Pricing of Public Offering of Common Stock
Wednesday, March 17, 2010
Theravance Announces Proposed Public Offering of Common Stock
Thursday, February 25, 2010
Theravance to Present at Investor Conferences in March 2010
Thursday, February 11, 2010
Theravance Reports Fourth Quarter and Full Year 2009 Financial Results
Wednesday, February 3, 2010
Theravance to Report Fourth Quarter and Full Year 2009 Financial Results on February 11, 2010
Thursday, January 28, 2010
Theravance Announces Receipt of Additional FDA Communication Regarding Telavancin NDA for the Treatment of Nosocomial Pneumonia
Thursday, January 7, 2010
Theravance to Present at the 28th Annual J.P. Morgan Healthcare Conference
Wednesday, December 2, 2009
Theravance to Present at the Deutsche Bank 2009 Biotech Boston Confab
Monday, November 30, 2009
Theravance Announces That EMEA Has Completed the Validation Phase for the Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections
Friday, November 27, 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Thursday, November 5, 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV( TM ) (telavancin) in the United States
Tuesday, November 3, 2009
Theravance to Present at the 18th Annual Credit Suisse Health Care Conference
Wednesday, October 28, 2009
Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe
Tuesday, October 27, 2009
Theravance Reports Third Quarter 2009 Financial Results
Tuesday, October 27, 2009
GlaxoSmithKline and Theravance commence Phase III Horizon programme to develop a next-generation treatment for COPD
Thursday, October 22, 2009
Theravance Earns $20 Million Milestone Under Telavancin Collaboration Agreement

www.VIBATIV.com